world1 outlet covering this

FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes

First publishedJun 15, 20:44 UTC

Last updatedJul 12, 12:32 UTC · 13m ago

↻

each logo = when that outlet publishedlast updated on Braven

Story signals

How strong is this topic?

High significance means broad impact or urgency. Source trust reflects the average authority of outlets covering the story.

Significance5.3

Weighted from impact, urgency, coverage breadth, and topic sensitivity.

Source trust10.0

Average reliability level of outlets included in this topic.

Outlets1

Independent sources contributing to this topic cluster.

More outlets usually means a more confirmed developing story.

The report

On June 12, 2026, the U.S. Food and Drug Administration granted accelerated approval to Tzield (teplizumab) for a new indication, to delay the decline of insulin production in pediatric patients ages 8 through 17 years who have been recently diagnosed with Stage 3 type 1 diabetes (T1D).

Read the full report at FDA ↗

Related in the knowledge graph

organizationCertain Pediatric Patients organizationDiabetes. On June organizationDrug Administration organizationFDA Approves New Indication organizationRecently Diagnosed Stage organizationStage organizationType organizationTzield

Sources (1)

Avg source rating 10.0/10

FDA10